Home›Trial›NCT05503927
NCT05503927ENROLLING BY INVITATION

A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy

Study Summary

This is an observational, retrospective, cohort study using administrative insurance claims data. The aim of this non-interventional study (NIS) is to compare maternal, fetal and infant outcomes of women exposed to Wegovy during pregnancy to a reference population not exposed to Wegovy, so that participants and healthcare providers can make informed treatment decisions.

Conditions
PregnancyObesityOverweight
Interventions / Drugs
No Intervention
View on ClinicalTrials.gov ↗
Sponsor
NVO
Novo Nordisk
Diabetes/Obesity
F12/100
Study Details
Enrollment1139 participants
Primary Completion—
Lead SponsorNovo Nordisk A/S
Data Retrieved2026-04-11 02:55:47.366886+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 1,139 participants
Sponsor Catalyst Profile

Novo Nordisk (NVO) is the sponsoring company for this trial. BiotechSign currently grades this company F (12/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NVO Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.